Enterococcus faecalis is a Gram-positive, facultative anaerobic bacterium that is a normal inhabitant of the human intestine. It is a member of the Enterococcus genus, which includes several species of bacteria that are commonly found in the environment and in the human body. Enterococcus faecalis is known to cause a wide range of infections, including urinary tract infections, endocarditis, and bacteremia. Despite its clinical significance, there is still much to be learned about this microbe. This article will explore the current understanding of Enterococcus faecalis, including its structure, physiology, genetics, and virulence factors.
Enterococcus faecalis is a small, Gram-positive, spherical bacterium. It is approximately 1.5-2 µm in diameter and is non-motile. The cell wall of Enterococcus faecalis is composed of a thick peptidoglycan layer, which is surrounded by a thin layer of lipoteichoic acid. The cell wall is responsible for the bacterium’s resistance to a variety of antibiotics, including penicillin and vancomycin.
Enterococcus faecalis is a facultative anaerobe, which means it can grow in both aerobic and anaerobic environments. It is able to utilize a variety of carbon sources, including glucose, fructose, sucrose, and glycerol. It is also capable of utilizing a variety of nitrogen sources, including ammonia, nitrate, and nitrite. Enterococcus faecalis is able to survive in a wide range of temperatures, pH levels, and salt concentrations.
Enterococcus faecalis is a genetically diverse species, which can be divided into several distinct clades. These clades are differentiated by their genetic makeup, which can be used to determine the virulence potential of a particular strain. Enterococcus faecalis is capable of producing a variety of virulence factors, including enterococcal surface protein (Esp), cytolysin, and gelatinase. These virulence factors are responsible for the bacterium’s ability to cause a wide range of infections.
Enterococcus faecalis is a major cause of nosocomial infections, which are infections acquired in a healthcare setting. The most common infections caused by Enterococcus faecalis are urinary tract infections, bacteremia, and endocarditis. These infections are often difficult to treat due to the bacterium’s resistance to many antibiotics. Enterococcus faecalis is also known to cause opportunistic infections in immunocompromised individuals.
Enterococcus faecalis is a Gram-positive, facultative anaerobic bacterium that is a normal inhabitant of the human intestine. It is a major cause of nosocomial infections, including urinary tract infections, bacteremia, and endocarditis. Despite its clinical significance, there is still much to be learned about this microbe. This article has explored the current understanding of Enterococcus faecalis, including its structure, physiology, genetics, and virulence factors.
1.
Financial hardship for cancer survivors due to high-cost immunotherapies, especially for blood cancer patients
2.
In-person and Virtual Palliative Care Are Both Beneficial for Advanced Lung Cancer Patients.
3.
Kidney cancer: Understanding what a renal cell carcinoma diagnosis means
4.
AI tool automates liver tumor detection and monitoring
5.
FDA Bans Red Dye No. 3 From Foods, Ingested Drugs
1.
Using Node Technology to Fight Breast Cancer: A New Hope for Early Detection
2.
Advances in Cancer Detection: From Genetic Risk to Molecular Biomarkers
3.
Unlocking the Power of Cryoprecipitate: A Comprehensive Guide
4.
How Cancer Cells Evade Immune Destruction and the Fight Back
5.
Unlocking The Causes And Risk Factors Of Breast Cancer
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
2.
Current Scenario of Cancer- Q&A Session to Close the Gap
3.
CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation